---
title: "Psilocybin (COMP360) in Treatment-resistant depression: Lithium and thyroid hormone augmentation"
description: "Formulary evidence on Psilocybin (COMP360) in Treatment-resistant depression: Lithium and thyroid hormone augmentation. Topics: CANMAT guideline: lithium and triiodothyronine as second-line adjuncts, NICE guideline: lithium and liothyronine augmentation and lithium monitoring, VA/DoD guideline: lithium and liothyronine with insufficient evidence for or against, VA/DoD guideline: liothyronine remission and cautions, and 7 further topics. 11 evidence topics quoted from 10 sources."
canonical: "https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/product-information-and-disease-description/lithium-and-thyroid-hormone-augmentation"
published: "2026-11-18T10:42:20-05:00"
modified: "2026-11-18T10:42:20-05:00"
---

# Psilocybin (COMP360) in Treatment-resistant depression: Lithium and thyroid hormone augmentation

<a id="heading-2.2.2.1.3"></a>

## 2.2.2.1.3 Lithium and Thyroid Hormone Augmentation

<a id="topic-2.2.2.1.3-1"></a>

### CANMAT guideline: lithium and triiodothyronine as second-line adjuncts

> “Both medications were included in a network meta-analysis evaluating all adjunctive options. While both lithium and triiodothyronine had evidence for efficacy, the included RCTs predated 2003, had small sample sizes and involved adjunctive use with TCAs only. Lithium also requires serum level monitoring and triiodothyronine requires monitoring of thyroid levels. Hence, lithium and triiodothyronine continue to be second-line recommendations.”

Source: [Lam et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11351064/)

<a id="topic-2.2.2.1.3-2"></a>

### NICE guideline: lithium and liothyronine augmentation and lithium monitoring

> “combining an antidepressant medication with a second-generation antipsychotic (for example, aripiprazole, olanzapine, quetiapine or risperidone) or lithium”
> “augmenting antidepressants with electroconvulsive therapy (see the recommendations on electroconvulsive therapy for depression), lamotrigine, or triiodothyronine (liothyronine).”
> “For people with depression taking lithium, assess weight, renal and thyroid function and calcium levels before treatment and then monitor at least every 6 months during treatment, or more often if there is evidence of significant renal impairment.”
> “plasma lithium levels should not exceed 1.0 mmol/L (therapeutic levels for augmentation of antidepressant medication are usually at or above 0.4 mmol/L; consider levels 0.4 to 0.6 mmol/L for older people aged 65 or above)”
> “monitor at each review for signs of lithium toxicity, including diarrhoea, vomiting, coarse tremor, ataxia, confusion and convulsions”

Source: [NICE (2022)](https://www.nice.org.uk/guidance/ng222/chapter/Recommendations)

<a id="topic-2.2.2.1.3-3"></a>

### VA/DoD guideline: lithium and liothyronine with insufficient evidence for or against

> “Medications with Insufficient Evidence to Support For or Against”
> “Lithium augmentation resulted in a reduction in depressive symptoms with a clinically meaningful NNT of five patients.”
> “However, Papadimitropoulou et al. (2017) found no difference in symptom improvement and remission in patients who received lithium augmentation versus placebo augmentation.”
> “In addition, lithium usage requires monitoring of lithium blood levels (therapeutic blood level is between 0.6 – <1.0 milliequivalents per liter [mEq/L] while potentially toxic blood levels are >1.5 mEq/L), and monitoring of thyroid function.”

Source: [VA/DoD (2022)](https://www.healthquality.va.gov/guidelines/MH/mdd/VADoDMDDCPGFinal508.pdf)

<a id="topic-2.2.2.1.3-4"></a>

### VA/DoD guideline: liothyronine remission and cautions

> “Liothyronine augmentation at the dose of 50 µg/day resulted in a remission rate of 25.7% with a mean time to remission of 5.3 weeks in the STAR*D study.”
> “Liothyronine should be prescribed with caution in patients with cardiovascular disease/arrhythmias, diabetes, renal impairment, or untreated adrenal insufficiency.”

Source: [VA/DoD (2022)](https://www.healthquality.va.gov/guidelines/MH/mdd/VADoDMDDCPGFinal508.pdf)

<a id="topic-2.2.2.1.3-5"></a>

### Third-step augmentation: lithium versus triiodothyronine

> “A total of 142 adult outpatients with nonpsychotic major depressive disorder who had not achieved remission or who were intolerant to an initial prospective treatment with citalopram and a second switch or augmentation trial were randomly assigned to augmentation with lithium (up to 900 mg/day; N=69) or with T(3) (up to 50 mug/day; N=73) for up to 14 weeks.”
> “After a mean of 9.6 weeks (SD=5.2) of treatment, remission rates were 15.9% with lithium augmentation and 24.7% with T(3) augmentation, although the difference between treatments was not statistically significant. Lithium was more frequently associated with side effects (p=0.045), and more participants in the lithium group left treatment because of side effects (23.2% versus 9.6%; p=0.027).”

Source: [Nierenberg et al. (2006)](https://pubmed.ncbi.nlm.nih.gov/16946176/)

<a id="topic-2.2.2.1.3-6"></a>

### Lithium augmentation versus placebo: meta-analysis

> “Nine trials that included 237 patients were selected. The odds ratio for response to lithium vs. placebo in all contrasts combined was 2.89 (95% CI 1.65, 5.05, z=3.72, p=0.0002).”
> “Adjunctive lithium was effective with TCAs (7 contrasts) and with second generation agents (3 contrasts). Discontinuation due to adverse events was infrequent and did not differ between lithium and placebo.”
> “The meta-analysis is limited by the small size and number of trials and limited data for treatment resistant patients.”

Source: [Nelson et al. (2014)](https://pubmed.ncbi.nlm.nih.gov/25069082/)

<a id="topic-2.2.2.1.3-7"></a>

### Network meta-analysis of augmentation agents: lithium and thyroid hormones

> “In order of decreasing efficacy, T3, nortriptyline, aripiprazole, brexpiprazole, quetiapine, lithium, modafinil, olanzapine (fluoxetine), cariprazine and lisdexamfetamine were statistically significant compared to placebo, with RRs ranging from 1.18 (1.03–1.37) for lisdexamfetamine to 1.90 (1.16–3.11) for T3.”
> “However, we should acknowledge that remission rates were not significant compared to placebo.”
> “Nevertheless, in a post-hoc sub-analysis of only three short-term studies (≤3 weeks) we found that response rates were not significant as compared to placebo (RR= 1.79; 0.48–6.67).”

Source: [Nuñez et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9328668/)

<a id="topic-2.2.2.1.3-8"></a>

### Thyroid hormone augmentation in unipolar treatment-resistant depression: meta-analysis

> “Based on the screening of these records, we identified 10 studies that met the inclusion criteria (total number of patients = 663). The comparison of response to thyroid hormones vs. placebo resulted in an odds ratio of 1.56 (95% CI: 0.50-4.84). Similarly, the comparison of response to thyroid hormones vs. lithium resulted in an odds ratio of 1.91 (95% CI: 0.85-4.26).”
> “According to this review and meta-analysis, there is not sufficient evidence to support the use of adjunctive thyroid hormones for treatment-resistant unipolar depression.”

Source: [Lorentzen et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/31977066/)

<a id="topic-2.2.2.1.3-9"></a>

### Lithium versus quetiapine augmentation over 12 months

> “Participants in the quetiapine group had a significantly lower overall burden of depressive symptom severity than participants in the lithium group (area under the between-group differences curve -68·36 [95% CI -129·95 to -6·76; p=0·0296). Time to discontinuation did not significantly differ between the two groups. Quetiapine was more cost-effective than lithium.”
> “Results of the trial suggest that quetiapine is more clinically effective than lithium as a first-line augmentation option for reducing symptoms of depression in the long-term management of treatment-resistant depression, and is probably more cost-effective than lithium.”

Source: [Cleare et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40113355/)

<a id="topic-2.2.2.1.3-10"></a>

### Lithium augmentation versus switch to nortriptyline in adults aged 60 years or older

> “Remission occurred in 18.9% of patients in the lithium-augmentation group and 21.5% in the switch-to-nortriptyline group; rates of falling were similar in the two groups.”
> “In our trial, less than 10% of the patients who switched to bupropion or had augmentation with lithium both reached and maintained the target dose and had remission.”

Source: [Lenze et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10568698/)

<a id="topic-2.2.2.1.3-11"></a>

### Lithium label: boxed warning on toxicity and renal effects

> “Lithium toxicity is closely related to serum lithium levels, and can occur at doses close to therapeutic levels. Facilities for prompt and accurate serum lithium determinations should be available before initiating therapy”
> “The toxic concentrations for lithium (≥1.5 mEq/L) are close to the therapeutic range (0.8 to 1.2 mEq/L).”
> “Chronic lithium therapy may be associated with diminution of renal concentrating ability, occasionally presenting as nephrogenic diabetes insipidus, with polyuria and polydipsia.”

Source: [Lithobid prescribing information (2022)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/018027s069lbl.pdf)

## Related pages
- [Psilocybin (COMP360): Treatment-resistant depression](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: Terms and abbreviations](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/terms-and-abbreviations.md)
- [Psilocybin (COMP360): Treatment-resistant depression](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/executive-summary) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/executive-summary.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: Product information and disease description](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/product-information-and-disease-description.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: Clinical evidence](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/clinical-evidence.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: Economic information and modeling report](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/economics) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/economics.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: References](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/references) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/references.md)
